Differences Between Intravenous and Subcutaneous Modes of Administration in Oncology from the Patient, Healthcare Provider, and Healthcare System Perspectives: A Systematic Review
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Background While patients with cancer have traditionally received oncology treatments through intravenous (IV) administration, some therapies are becoming available via alternative modes of administration, such as subcutaneous (SC). This study aimed to evaluate IV versus SC therapy administration from the perspectives of the patient, healthcare provider (HCP), and healthcare system.Methods A systematic review was conducted, searching MEDLINE and Embase databases from 2000 to 2022. This was supplemented with grey literature searches of additional sources such as conference proceedings. Observational studies and clinical trials were included if they assessed adult patients with any cancer type who were treated with pharmacologic therapies administered via IV or SC and included patient- or HCP-reported outcomes or healthcare system perspectives on the mode of administration. Records identified by the literature search were screened by two independent reviewers. Included studies were data extracted by a single reviewer and validated by a second reviewer and synthesized using a narrative approach.Results After screening, 33 unique studies were included in the systematic review. Patients and HCPs reported substantially more favorable preference rates for SC over IV treatment. Additionally, from the patient perspective there were reductions in treatment time and economic burden for SC compared with IV therapy. From the HCP's perspective, treatment time was consistently reduced by SC compared with IV treatment administration. Although information on the impact of SC and IV treatments for oncology on healthcare systems was limited, the use of SC formulations showed consistent cost savings (direct costs) and time savings from this perspective considering various uptake scenarios compared with IV administration.Conclusion Compared with IV administration, SC oncology treatment is a preferred option by patients and HCPs, increasing optionality and reducing treatment time while simultaneously increasing capacity and reducing the financial burden on healthcare systems.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003583 · Cited by 5,148
Krohe, M., Eek, D., Mazar, I., Horsfield, A., Pompilus, F., Friebe, R., & Shields, A. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s106629 · Cited by 265 · cited 1×
“While many cancer therapies are delivered through intravenous (IV) administration [1], over the past decade, novel therapies have increasingly been made available via alterna‑ tive modes of administration, such as subcu‑ taneous (SC) or intramuscular injections, and several existing treatments that…”
Pivot, X., Gligorov, J., Müller, V., Barrett-Lee, P., Verma, S., Knoop, A., Curigliano, G., Semiglazov, V., López-Vivanco, G., Jenkins, V., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70383-8 · Cited by 230 · cited 2×
“In total, 12 studies (7 trials and 5 observational studies) were identified that reported patient preference data [11, 13, 17–20, 24, 31, 33, 35, 42, 43], 8 (5 trials and 3 observational studies) reported information related to patient satisfac‑ tion [18, 31, 34, 35, 39, 41, 43–45], 18 (16 obser‑…”
Pivot, X., Gligorov, J., Müller, V., Curigliano, G., Knoop, A., Verma, S., Jenkins, V., Scotto, N., Osborne, S., Fallowfield, L., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu364 · Cited by 177 · cited 3×
“%) or from SC to IV (77.0–89.8%), and these propor‑ tions remained substantially higher for SC treat‑ ment than the proportions with a preference for IV treatment (8.9–15.6%; Table 1) [17, 24, 35, 49].”
InfluentialRummel, M., Kim, T. M., Aversa, F., Brugger, W., Capochiani, E., Plenteda, C., Re, F., Trask, P., Osborne, S., Smith, R., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw685 · Cited by 154 · cited 4×
“%) or from SC to IV (77.0–89.8%), and these propor‑ tions remained substantially higher for SC treat‑ ment than the proportions with a preference for IV treatment (8.9–15.6%; Table 1) [17, 24, 35, 49].”
InfluentialDavies, A., Merli, F., Mihaljević, B., Mercadal, S., Siritanaratkul, N., Solal-Céligny, P., Boehnke, A., Berge, C., Genevray, M., Zharkov, A., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30078-9 · Cited by 125
Jackisch, C., Kim, S.-B., Semiglazov, V., Melichar, B., Pivot, X., Hillenbach, C., Stroyakovskiy, D., Lum, B. L., Elliott, R., Weber, H. A., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu524 · Cited by 114 · cited 2×
“…14 included stud‑ ies (11 trials and t3hree observational studies) reported treatment‑related adverse/safety events and identified that injection site reactions were reported most frequently for SC treatments (e.g., pain, swelling, and erythema) [12, 17, 19, 21, 24, 33–37, 42, 43, 47, 50].”
De Cock, E., Pivot, X., Hauser, N., Verma, S., Kritikou, P., Millar, D., & Knoop, A. (2016) · Cancer Medicine · doi:10.1002/cam4.573 · Cited by 112 · cited 4×
“Mean reduction in total therapy time for SC compared with IV administration among studies that reported this measure was typically 2 h or more [14, 16, 22, 25–29, 34, 38, 43, 46].”
InfluentialSalar, A., Avivi, I., Bittner, B., Bouabdallah, R., Brewster, M., Catalani, O., Follows, G., Haynes, A., Hourcade-Potelleret, F., Janikova, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.2631 · Cited by 98 · cited 2×
“…14 included stud‑ ies (11 trials and t3hree observational studies) reported treatment‑related adverse/safety events and identified that injection site reactions were reported most frequently for SC treatments (e.g., pain, swelling, and erythema) [12, 17, 19, 21, 24, 33–37, 42, 43, 47, 50].”
Cited by
Felip, E., Rojas, C. I., Schenker, M., Kowalski, D. M., Casarini, I. A., Csöszi, T., Şendur, M. A. N., Martins, J., Calles Blanco, A., Wang, C.-C., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.03.012 · Cited by 40
Desai, M. G., Kundu, A., Hageman, M. J., Lou, H., Tenjarla, S. N., Sun, C. C., Zhang, F., & Rahman, O. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01132-8 · Cited by 13
“However, newer drug delivery devices with higher volume limits, such as on-body delivery systems (OBDSs), allow for the administration of low-concentration, large-volume formulations (3, 7, 8).”
Cohen, G. L., Coetzee, C., Walton, C. A., Reig, Ò., Cho, B. C., McAdam, G. L., Rojas, C. I., Rodríguez, L. M., Pápai, Z., Chan, S. W., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115709 · Cited by 13
Szabados, B. E., Guerrero‐Ramos, F., Grande, E., Grivas, P. D., Grünwald, V., Miguel, M. C., Hussain, S. A., Kulkarni, G. S., Wilson, A. L., Shore, N. D., et al. (2025) · Oncology and Therapy · doi:10.1007/s40487-025-00334-6 · Cited by 6
“In addition, many patients prefer SC over IV administration because of shorter treatment times and decreased discomfort [32–34 , 38].”
Franzese, C., Hawthorne, J., Katsaros, D., & Coyne, M. (2025) · Patient Preference and Adherence · doi:10.2147/ppa.s515565 · Cited by 7
“12 Similar preference for SC treatments has been observed in oncology therapeutic areas, both when IV and SC treatment options are administered in clinic 9,89 and when home administration has been explored.”
Metadata
- Authors
- Aguiar-Ibáñez, R., Fotheringham, I., Mittal, L., Sillah, A., & Pathak, S.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Venue
- Advances in Therapy
- Published
- 2024-10-19
- Volume
- 41
- Issue
- 12
- Pages
- 4396-4417
- ISSN
- 0741-238X (ISSN-L)
- 1865-8652
- OpenAlex
- W4403566765
- Cited by
- 19
- References
- 54
- Citations by year
- 2026: 13 · 2025: 6
- FWCI
- 2.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Advances in Therapy (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Merck & Co., Inc., Rahway, NJ, USA
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Safe Handling of Antineoplastic Drugs
- Keywords
- subcutaneous administration, intravenous administration, cancer therapy, patient preferences, healthcare provider preferences, treatment duration, economic burden, health care costs, healthcare system perspective, patient-reported outcomes
- MeSH terms
- Antineoplastic Agents, Health Personnel, Humans, Injections, Subcutaneous, Neoplasms, Patient Preference, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Differences Between Intravenous and Subcutaneous Modes of Administration in Oncology from the Patient, Healthcare Provider, and Healthcare System Perspectives: A Systematic Review. https://app.cochat.ai/papers/10.1007/s12325-024-02985-9
- The paper
- Aguiar-Ibáñez, R., Fotheringham, I., Mittal, L., Sillah, A., & Pathak, S. (2024). Differences Between Intravenous and Subcutaneous Modes of Administration in Oncology from the Patient, Healthcare Provider, and Healthcare System Perspectives: A Systematic Review. Advances in Therapy. https://doi.org/10.1007/s12325-024-02985-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.